PICO 및 근거표

| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
| :------------------------------------------ | :------------- | :------------------ | :---------------------------------- | :------------------- |
| 7 Acute respiratory illness subsequently documented as influenza-related | 2 | 180 | Odds Ratio (M-H, Fixed, 95% CI) | 0.19 [0.07, 0.48] |
| 7.1 FEV1>70% predicted | 1 | 45 | Odds Ratio (M-H, Fixed, 95% CI) | 0.12 [0.01, 1.11] |
| 7.2 FEV150-69% predicted | 1 | 33 | Odds Ratio (M-H, Fixed, 95% CI) | 0.46 [0.07, 2.98] |
| 7.3 FEV1<50% predicted | 1 | 47 | Odds Ratio (M-H, Fixed, 95% CI) | 0.11 [0.01, 0.99] |
| 7.4 Chronic bronchitis patients | 1 | 55 | Odds Ratio (M-H, Fixed, 95% CI) | 0.19 [0.04, 0.96] |
| 8 Early acute respiratory illness | 1 | 250 | Odds Ratio (M-H, Fixed, 95% CI) | 0.72 [0.34, 1.50] |
| 8.1 ARI within 1 week of vaccination | 1 | 125 | Odds Ratio (M-H, Fixed, 95% CI) | 1.02 [0.24, 4.26] |
| 8.2 ARI between 1 and 4 weeks after vaccination | 1 | 125 | Odds Ratio (M-H, Fixed, 95% CI) | 0.63 [0.27, 1.50] |
| 9 Hospitalisations | 2 | 180 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 0.33 [0.09, 1.24] |
| 9.1 Clinical exacerbations | 1 | 55 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 0.14 [0.01, 2.39] |
| 9.2 Influenza-related exacerbations | 1 | 125 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 0.41 [0.09, 1.89] |
| 10 Mortality | 2 | 180 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 0.87 [0.28, 2.70] |
| 11 Mortality related to acute respiratory infection | 1 | | Odds Ratio (M-H, Fixed, 95% CI) | Totals not selected |
| 12 Overall change in lung function (FEV1 in litres) | 1 | | Mean Difference (IV, Fixed, 95% CI) | Totals not selected |
| 13 Change in early lung function (FEV1 in litres) | 1 | | Mean Difference (IV, Fixed, 95% CI) | Totals not selected |
| 14 Local effects at Injection Site | 1 | | Odds Ratio (M-H, Fixed, 95% CI) | Totals not selected |
| 15 Systemic adverse effects | 1 | | Odds Ratio (M-H, Fixed, 95% CI) | Totals not selected |
| 16 Patients with early breathlessness | 1 | | Peto Odds Ratio (Peto, Fixed, 95% CI) | Totals not selected |
| 17 Patients with early tightness | 1 | | Peto Odds Ratio (Peto, Fixed, 95% CI) | Totals not selected |
| 18 Patients with early wheeze | 1 | | Peto Odds Ratio (Peto, Fixed, 95% CI) | Totals not selected |
| 19 Patients with early cough | 1 | | Peto Odds Ratio (Peto, Fixed, 95% CI) | Totals not selected |
| 20 Patients with early sputum production | 1 | | Peto Odds Ratio (Peto, Fixed, 95% CI) | Totals not selected |

## Comparison 2. Inactivated/ Live versus Inactivated/Placebo
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
| :------------------------------------------ | :------------- | :------------------ | :---------------------------------- | :------------------- |
| 1 Total exacerbations per patient | 2 | 1137 | Mean Difference (IV, Fixed, 95% CI) | 0.01 [-0.35, 0.37] |
| 2 Early exacerbations per patient | 1 | | Mean Difference (IV, Fixed, 95% CI) | Totals not selected |
| 3 Late exacerbations per patient | 1 | | Mean Difference (IV, Fixed, 95% CI) | Totals not selected |
| 4 Acute respiratory illness subsequently documented as influenza-related | 1 | | Odds Ratio (M-H, Fixed, 95% CI) | Totals not selected |
| 5 Patients with at least one influenza-like illness | 1 | | Odds Ratio (M-H, Fixed, 95% CI) | Totals not selected |
| 6 Patients with improvement in exacerbations | 1 | | Peto Odds Ratio (Peto, Fixed, 95% CI) | Totals not selected |
| 7 Patients with early improvements | 1 | | Peto Odds Ratio (Peto, Fixed, 95% CI) | Totals not selected |
| 8 Patients with late improvements | 1 | | Peto Odds Ratio (Peto, Fixed, 95% CI) | Totals not selected |
| 9 Early changes in lung function (% predicted FEV1) | 1 | | Mean Difference (IV, Fixed, 95% CI) | Totals not selected |
| 10 Early changes in lung function (FEV1/FVC %) | 1 | | Mean Difference (IV, Fixed, 95% CI) | Totals not selected |
| 11 Post immunisation lung function (FEV1) | 1 | | Mean Difference (IV, Fixed, 95% CI) | Totals not selected |
| 12 Patients with increase in lung function (1 category) | 1 | | Peto Odds Ratio (Peto, Fixed, 95% CI) | Totals not selected |
| 13 Patients with a decrease in lung function | 1 | | Peto Odds Ratio (Peto, Fixed, 95% CI) | Totals not selected |
| 14 FEV1 at end of study | 1 | | Mean Difference (IV, Fixed, 95% CI) | Totals not selected |
| 15 Patients with adverse effects (new upper respiratory tract symptoms) | 1 | | Peto Odds Ratio (Peto, Fixed, 95% CI) | Totals not selected |
| 16 Patients with early adverse effects | 2 | 2244 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 0.86 [0.63, 1.17] |
| 17 Days with early symptoms and signs | 1 | | Mean Difference (IV, Fixed, 95% CI) | Totals not selected |

<PAGE>144